Gosuranemab - Biogen

Drug Profile

Gosuranemab - Biogen

Alternative Names: Anti-eTau; Anti-etau humanized IGG4 monoclonal antibody - Biogen; Anti-tau-mAb; BIIB092; BMS-986168; IPN-007

Latest Information Update: 09 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator iPierian
  • Developer Biogen; Bristol-Myers Squibb; iPierian
  • Class Monoclonal antibodies; Neuropsychotherapeutics
  • Mechanism of Action Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Progressive supranuclear palsy
  • Phase I Neurodegenerative disorders
  • Discontinued Cardiovascular disorders; Metabolic disorders

Most Recent Events

  • 03 Oct 2018 Gosuranemab - Biogen receives Fast Track designation for Progressive supranuclear palsy [IV,Infusion] in USA
  • 03 Oct 2018 Biogen completes enrolment in its phase II PASSPORT trial for Progressive supranuclear palsy (PSP) in USA (NCT03068468)
  • 05 Sep 2018 Phase-I clinical trials in Neurodegenerative disorders in USA (IV) (NCT03658135)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top